|View printer-friendly version|
|Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions|
Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190604005234/en/
VeriSeq NIPT Solution v2 (Photo: Business Wire)
VeriSeq NIPT Solution v2 provides accurate information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw. This noninvasive test provides an option to screen for aneuploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. Due to its high-sensitivity and high-specificity (low false-positive and false-negative rates), NGS-based NIPT minimizes the need for invasive testing procedures. The automated, reliable solution provides reagents, instruments, installation and training, and offers unprecedented turnaround times; laboratories can process up to 96 samples in approximately one day.
“Genome‐wide cell-free DNA screening allows not only for the detection
of common chromosomal aneuploidies, but also enables the identification
of rare autosomal aneuploidies (RAAs), as well as partial deletions and
duplications that are ≥7 Mb in size. Most RAAs are non-viable and result
in a miscarriage. However, in the mosaic state they may persist and
result in congenital malformations, intellectual disabilities, growth
restriction, unfavorable pregnancy outcome, as well as fetal uniparental
disomy,” said Professor
The clinical accuracy of VeriSeq NIPT Solution v2, with respect to outcomes determined by a clinical reference standard assessment, was demonstrated by evaluating more than 2,300 plasma samples from pregnant women with singleton and twin pregnancies undergoing prenatal screening for fetal chromosome aneuploidies and partial deletions and duplications of 7 Mb or greater. The study determined that VeriSeq NIPT Solution v2 provided highly sensitive and specific results – 98.8 percent passed assay quality control on the first pass.
Click here for more information on VeriSeq NIPT Solution v2.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
This release contains forward-looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding the expected availability
dates for, and field performance of, new products and services.
Important factors that could cause actual results to differ materially
from those in any forward-looking statements include challenges inherent
in developing, manufacturing, and launching new products and services,
and the other factors that are detailed in our filings with
Tina Amirkiai (USA)